$PBIO Recent Operational and Technical Highlights
Launch of our Revolutionary UST-Based System to Make High Quality, Stable, Water-Soluble Nanoemulsions of CBD Oil
We announced our entrance into the CBD market with the launch of a novel, proprietary processing system (the BaroShear K45) to revolutionize the manufacture of water-soluble, long-term stable, highly absorbable, nanoemulsified CBD Oil
We announced receipt of the initial three purchase orders for our BaroShear K45 nanoemulsification system
We hired pharma/biotech/lab instrumentation veteran Ken Micciche to direct the UST Program
We sent out quotations for potential BaroShear K45 purchases to multiple companies in the U.S. and Canada
We are close to completing the build-out of our GMP-compliant manufacturing laboratory, where we expect to showcase the BaroShear K45 and our new industrial scale, high volume (2 liters/minute) UST-based nanoemulsification systems
Expansion of our Recently Launched BaroFold Contract Services Business
We entered into a six-figure agreement with a new multi-national, multi-billion-dollar biopharma company
We began discussions towards an agreement with several additional multi-national, multi-billion-dollar companies
We expanded the contract services laboratory with additional specialized equipment and new methods/applications
Expanded Applications for our Core Suite of PCT and Constant Pressure-Based Instruments
Our proprietary PCT Platform was acknowledged to fill a pivotal role for tumor analysis in a novel workflow presented at a leading global gynecological cancer meeting. The presenters commented that data from the analysis of cancer tissue proteins excised by their novel PCT-based workflows could lead to improved clinical management of gynecological cancers.
At a major international conference in Australia, our PCT Platform was featured in 10 separate presentations by scientists from 17 research institutions worldwide. The presentations highlighted novel applications for the PCT Platform in cancer research and diagnostics.
The PCT Platform was identified by two prestigious research centers as pivotal for cancer biomarker discovery and potential clinical diagnostics in studies using preserved (i.e., formalin-fixed, paraffin-embedded, or FFPE) cancer biopsy tissue samples.
Earnings Call
The Company will hold an Earnings Conference Call at 4:30 PM EST on Thursday, December 19, 2019. To attend this teleconference via telephone, Dial-in: (844) 602-0380 (North America), (862) 298-0970 (International). Verbal Passcode: PBIO Third Quarter 2019 Financial Results Call. Replay Number (877) 481-4010 (North America), (919) 882-2331 (International). Replay ID Number: 57001. Teleconference Replay Available for 30 days.
https://www.otcmarkets.com/stock/PBIO/news/Pr...?id=249766
Launch of our Revolutionary UST-Based System to Make High Quality, Stable, Water-Soluble Nanoemulsions of CBD Oil
We announced our entrance into the CBD market with the launch of a novel, proprietary processing system (the BaroShear K45) to revolutionize the manufacture of water-soluble, long-term stable, highly absorbable, nanoemulsified CBD Oil
We announced receipt of the initial three purchase orders for our BaroShear K45 nanoemulsification system
We hired pharma/biotech/lab instrumentation veteran Ken Micciche to direct the UST Program
We sent out quotations for potential BaroShear K45 purchases to multiple companies in the U.S. and Canada
We are close to completing the build-out of our GMP-compliant manufacturing laboratory, where we expect to showcase the BaroShear K45 and our new industrial scale, high volume (2 liters/minute) UST-based nanoemulsification systems
Expansion of our Recently Launched BaroFold Contract Services Business
We entered into a six-figure agreement with a new multi-national, multi-billion-dollar biopharma company
We began discussions towards an agreement with several additional multi-national, multi-billion-dollar companies
We expanded the contract services laboratory with additional specialized equipment and new methods/applications
Expanded Applications for our Core Suite of PCT and Constant Pressure-Based Instruments
Our proprietary PCT Platform was acknowledged to fill a pivotal role for tumor analysis in a novel workflow presented at a leading global gynecological cancer meeting. The presenters commented that data from the analysis of cancer tissue proteins excised by their novel PCT-based workflows could lead to improved clinical management of gynecological cancers.
At a major international conference in Australia, our PCT Platform was featured in 10 separate presentations by scientists from 17 research institutions worldwide. The presentations highlighted novel applications for the PCT Platform in cancer research and diagnostics.
The PCT Platform was identified by two prestigious research centers as pivotal for cancer biomarker discovery and potential clinical diagnostics in studies using preserved (i.e., formalin-fixed, paraffin-embedded, or FFPE) cancer biopsy tissue samples.
Earnings Call
The Company will hold an Earnings Conference Call at 4:30 PM EST on Thursday, December 19, 2019. To attend this teleconference via telephone, Dial-in: (844) 602-0380 (North America), (862) 298-0970 (International). Verbal Passcode: PBIO Third Quarter 2019 Financial Results Call. Replay Number (877) 481-4010 (North America), (919) 882-2331 (International). Replay ID Number: 57001. Teleconference Replay Available for 30 days.
https://www.otcmarkets.com/stock/PBIO/news/Pr...?id=249766
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
